Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Equity Average (2016 - 2025)

Historic Equity Average for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to $3.1 billion.

  • Neurocrine Biosciences' Equity Average rose 1785.97% to $3.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.1 billion, marking a year-over-year increase of 1785.97%. This contributed to the annual value of $2.9 billion for FY2025, which is 2117.72% up from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Equity Average is $3.1 billion, which was up 1785.97% from $2.8 billion recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Equity Average peaked at $3.1 billion during Q4 2025, and registered a low of $1.2 billion during Q1 2021.
  • In the last 4 years, Neurocrine Biosciences' Equity Average had a median value of $2.3 billion in 2024 and averaged $2.1 billion.
  • In the last 5 years, Neurocrine Biosciences' Equity Average skyrocketed by 7437.93% in 2021 and then soared by 683.72% in 2025.
  • Neurocrine Biosciences' Equity Average (Quarter) stood at $1.3 billion in 2021, then soared by 61.29% to $2.1 billion in 2023, then rose by 25.38% to $2.7 billion in 2024, then grew by 17.86% to $3.1 billion in 2025.
  • Its Equity Average stands at $3.1 billion for Q4 2025, versus $2.8 billion for Q3 2025 and $2.6 billion for Q2 2025.